octanate 250iu
octapharma pharmazeutika produktionsges. m.b.h. - human blood coagulation factor viii - powder lyophilized for solution for injection - 250iu/vial
immunate powder and solvent for solution for injection
baxter ag - human blood coagulation factor viii/von willebrand factor(vwf:rco) - powder and solvent for solution for injection - 250iu/190iu
octanate 500iu powder and solvent for solution for injection
octapharma pharmazeutika produktionsges. m.b.h. - human blood coagulation factor viii - powder and solvent for solution for injection - 50iu/ml
octanate 250iu powder and solvent for solution for injection
wellchem pharmaceuticals pte ltd - coagulation factor viii (human) - injection, powder, for solution - 250 iu/5 ml - coagulation factor viii (human) 250 iu/5 ml vial
replenine-vf, 50 iu/ml human factor ix, a powder for solution.
bio products laboratory limited - factor ix, human - powder for solution for injection - factor ix, human 50 international unit(s)/millilitre - antihemorrhagics
kovaltry 250 iu
bayer israel ltd - recombinant human coagulation factor viii - powder and solvent for solution for injection - recombinant human coagulation factor viii 250 iu - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). kovaltry can be used for all age groups.
feiba 500u
takeda israel ltd - factor viii inhibitor bypassing fraction - powder and solvent for solution for injection/infusion - factor viii inhibitor bypassing fraction 500 u/vial - factor viii inhibitor bypassing activity - factor viii inhibitor bypassing activity - control of bleeding episodes in haemophilia a patients with factor viii inhibitors and also in patients with acquired factor viii inhibitors.control of bleeding in hemophilia b patients with inhibitors, if no other specific treatment is available.
feiba 1000u
takeda israel ltd - factor viii inhibitor bypassing fraction - powder and solvent for solution for injection/infusion - factor viii inhibitor bypassing fraction 1000 u/vial - factor viii inhibitor bypassing activity - factor viii inhibitor bypassing activity - control of bleeding episodes in haemophilia a patients with factor viii inhibitors and also in patients with acquired factor viii inhibitors .control of bleeding in hemophilia b patients with inhibitors, if no other specific treatment is available.
optivate 500 i.u
kamada ltd, israel - factor viii; von willebrand factor - powder for solution for injection - factor viii 500 iu/vial; von willebrand factor 1300 iu/vial - von willebrand factor and coagula-tion factor viii in combination - von willebrand factor and coagula-tion factor viii in combination - treatment and prophylaxis of bleeding with haemophilia a (congenital factor viii deficiency).
optivate 1000 i.u
kamada ltd, israel - factor viii; von willebrand factor - powder for solution for injection - factor viii 1000 iu/vial; von willebrand factor 2600 iu/vial - von willebrand factor and coagula-tion factor viii in combination - von willebrand factor and coagula-tion factor viii in combination - treatment and prophylaxis of bleeding with haemophilia a (congenital factor viii deficiency).